Loading…

MedtronicMDTCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

World's largest pure-play medical device maker, spanning cardiac devices, surgical robotics and neuromodulation.

Momentum leader 86
Mkt cap
$129B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$739M
20-day average traded
Fwd P/E
16.8×
forward earnings
ROIC−WACC
+0.8 pp
WACC 7.5%
Hurdle
+5 pp
Req g minus delivered
Official | Implied
A / AA
agencies · bond market
Next earnings
6 days
24 Nov 2026
Close · USD$100.72
1D-1.6%
1W-0.9%
1M+6.4%
3M+9.1%
6M+30.0%
YTD+6.7%
1Y+7.2%
ATR %2.4%
Beta0.18
52w lowhigh5.2% off high

What Medtronic does

World's largest pure-play medical device maker, spanning cardiac devices, surgical robotics and neuromodulation.

Sells implants and devices to hospitals, with recurring revenue from single-use parts used in procedures, and heart-rhythm devices carrying the business. It is Irish-domiciled, and announced in 2025 a plan to separate its insulin-pump business, MiniMed.

Products and services

  • Cardiac rhythm & pacing
  • Surgical robotics (Hugo) & surgical innovations
  • Neuroscience (spine, neuromodulation)
  • Diabetes (retained MiniMed stake)

Customers

  • Hospitals
  • Cardiologists/surgeons
  • Patients

Where it sits in the supply chain

  • Healthcare
  • Medical devices
  • Cardiac, surgical, neuroscience devices

What could go right

  • Surgical robotics adoption ramp
  • Value of retained MiniMed diabetes stake

What could go wrong

  • Device pricing/reimbursement pressure
  • Competitive surgical robotics landscape vs Intuitive

Moat: wide (scale, IP / patents, switching costs). Broad device portfolio with deep physician relationships and regulatory/IP barriers across many categories.

Headquarters: Dublin, Ireland (operating HQ Minneapolis, USA) · Founded: 1949 · Employees: 95,000

Named competitors

Medtronic at a glance

Size Medtronic (MDT) is a United States Health Care company (Medical Specialties) with a market value of $129B, the 94th largest of 3,085 United States companies the cockpit tracks. Shares closed at $100.72 on 18 Nov 2026.

Performance Over six months the shares gained 30.0%, against +22.2% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 9.8% over the last twelve months (peer median +8.4%); the operating margin is 19.9% (peer median 21.2%).

Valuation It trades at 16.8× forward earnings against a peer median of 25.4× (4th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.8 points above its cost of capital (7.5% WACC).

Backlog Backlog (remaining performance obligations) was $400M at 31 Jul 2026, flat on a year earlier — 0.0 years of trailing revenue. Backlog detail →

Credit Medtronic has 4 bonds outstanding ($5.74B), rated A by the agencies and trading like AA at a weighted spread of 62 bp.

Short interest Short interest is 1.8% of the free float (30 Oct 2026).

Next results Next results expected around 24 Nov 2026 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026MDT 130Peer median 122
Six months, rebased to 100: Medtronic against the median of its 20 peers (local-currency closes).

Medtronic financials

Reported figures in USD; fiscal year ends 2026-04-30. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$37.5B$36.4B$33.5B$32.4B$31.2B
Revenue growth—+8%+4%+4%—
Gross profit$22.7B$21.9B$20.1B$19.5B$18.9B
EBITDA$10.4B$10.0B$9.05B$8.38B$8.21B
Net income$5.23B$4.80B$4.66B$3.68B$3.76B
Free cash flow$6.13B$5.43B$5.18B$5.20B$4.58B
Capital expenditure$1.90B$1.90B$1.86B$1.59B$1.46B
Total debt$28.2B$29.1B$29.6B$26.0B$25.4B

Quarterly statements and history in the cockpit →

Medtronic competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%0%+10%+20%SYKISRGDHRELABTTMOBSXEWBDXIDXXSHLMDLNA7741WATGEHCALCMTDRMD300760MDT6-month return →1-month return →
Up and to the right = strong over both horizons. Medtronic is the large dot.

Fundamentals: revenue growth against valuation

0%+5%+10%+15%+20%20×30×SYKISRGDHRELABTTMOBSXEWBDXIDXXSHLMDLNA7741WATGEHCALCMTD300760MDTRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Medtronic is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%0%10%20%30%SYKISRGDHRELABTTMOBSXEWBDXIDXXSHLMDLNA7741WATGEHCALCMTDRMD300760MDTGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Medtronic is the large dot.

Medtronic competitors and peer comparison

Head to head with its named competitors (MDT vs ABT vs BSX vs SYK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Abbott Laboratories ABT$181B+18%+10%14%17.9×16.5%
Boston Scientific BSX$63.3B-23%+9%21%14.1×5.8%
Stryker SYK$121B-1%+8%25%19.9×10.7%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%

How Medtronic compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Medtronic against its 20 peers (data as of 18 Nov 2026)
MeasureMDTPeer medianRank in peer set
1-month return+6.4%+5.5%9th highest of 21
6-month return+30.0%+22.2%8th highest of 21
Distance from 52-week high-5.2%-9.1%7th highest of 21
Revenue growth (TTM)+9.8%+8.4%8th highest of 21
Operating margin19.9%21.2%10th lowest of 21
Forward P/E16.8×25.4×4th cheapest of 21
Growth the price implies (Req g, 7 yrs)9.1%16.2%6th least demanding of 21
Growth delivered (Del g)+3.8%+6.7%4th lowest of 21
Hurdle (Req g minus delivered)+5.2 pp+6.1 pp10th least demanding of 21
ROIC minus cost of capital+0.8 pp+3.7 pp9th lowest of 21
EV / EBITDA14.3×19.3×5th cheapest of 20
Net debt / EBITDA1.9×1.9×10th least indebted of 20
Bond spread62 bp75 bp2nd tightest of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Medtronic MDTUnited States$129B+30%+10%20%16.8×9.1%+3.8%
Stryker SYKUnited States$121B-1%+8%25%19.9×10.7%+11.8%
Intuitive Surgical ISRGUnited States$146B-6%+20%32%34.8×29.6%+18.2%
Danaher DHRUnited States$161B+34%+6%21%25.1×20.8%+2.0%
EssilorLuxottica EL.PAFrance$91.9B+5%+8%12%24.8×18.4%+14.6%
Abbott Laboratories ABTUnited States$181B+18%+10%14%17.9×16.5%+5.1%
Thermo Fisher Scientific TMOUnited States$257B+53%+8%19%25.7×21.3%+6.7%
Boston Scientific BSXUnited States$63.3B-23%+9%21%14.1×5.8%+15.2%
Edwards Lifesciences EWUnited States$60.5B+27%+13%29%32.3×17.1%+6.7%
Becton Dickinson BDXUnited States$58.9B+48%-7%16%16.3×-1.6%+0.3%
Idexx Laboratories IDXXUnited States$55.0B+26%+12%32%42.9×29.0%+9.7%
Siemens Healthineers SHL.DEGermany$53.7B+27%+1%14%18.9×9.6%+5.6%
Medline MDLNUnited States$51.5B+8%+12%6%25.6×15.9%+9.9%
Agilent Technologies AUnited States$50.0B+56%+9%24%27.0×23.3%+5.4%
Hoya 7741.TJapan$49.0B-16%+13%32%27.7×14.1%+11.6%
Waters WATUnited States$45.8B+37%+81%10%29.1×48.1%+6.0%
GE HealthCare GEHCUnited States$37.8B+30%+7%14%15.6×5.0%+3.7%
Alcon ALC.SWSwitzerland$36.9B+18%+1%12%21.5×12.2%+6.1%
Mettler Toledo MTDUnited States$34.6B+60%+7%29%33.7×20.1%+5.5%
ResMed RMDUnited States$34.1B+16%+9%34%19.7×5.7%+12.1%
Shenzhen Mindray Bio-Medical Electronics 300760.SZChina$33.6B+15%+5%28%27.3×1.0%+9.7%

Medtronic bonds and credit

Medtronic has 4 bonds outstanding with $5.74B face value. The agencies rate it A; its bonds trade like AA. Weighted yield 5.55%, a spread of 62 bp over government bonds.

Every bond, yield and spread in the cockpit →

Medtronic backlog

Medtronic reported $400M of remaining performance obligations at 31 Jul 2026, flat from a year earlier and flat from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.

Questions

Who are Medtronic's main competitors?
Named competitors: Abbott Laboratories (ABT), Boston Scientific (BSX), Stryker Corporation (SYK), Johnson & Johnson (JNJ). The cockpit's measured peer set (industry) also includes Stryker (SYK), Intuitive Surgical (ISRG), Danaher (DHR), EssilorLuxottica (EL.PA), Abbott Laboratories (ABT), Thermo Fisher Scientific (TMO).
Is Medtronic expensive compared with its peers?
On forward p/e it trades at 16.8× against a peer median of 25.4×, 4th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Medtronic stock performed?
Over six months to 18 Nov 2026 the shares returned +30.0% against +22.2% for the median peer; over one year +7.2%.
What is Medtronic's backlog?
Medtronic's remaining performance obligations (contracted revenue not yet recognised) were $400M at 31 Jul 2026, 0% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.